JP2017519008A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519008A5
JP2017519008A5 JP2016572697A JP2016572697A JP2017519008A5 JP 2017519008 A5 JP2017519008 A5 JP 2017519008A5 JP 2016572697 A JP2016572697 A JP 2016572697A JP 2016572697 A JP2016572697 A JP 2016572697A JP 2017519008 A5 JP2017519008 A5 JP 2017519008A5
Authority
JP
Japan
Prior art keywords
serelaxin
pharmaceutical formulation
patient
biological sample
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016572697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519008A (ja
JP6820748B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/054399 external-priority patent/WO2015189790A1/en
Publication of JP2017519008A publication Critical patent/JP2017519008A/ja
Publication of JP2017519008A5 publication Critical patent/JP2017519008A5/ja
Application granted granted Critical
Publication of JP6820748B2 publication Critical patent/JP6820748B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016572697A 2014-06-13 2015-06-10 Gdf−15を減少させるためのセレラキシンの使用 Expired - Fee Related JP6820748B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462011744P 2014-06-13 2014-06-13
US62/011,744 2014-06-13
PCT/IB2015/054399 WO2015189790A1 (en) 2014-06-13 2015-06-10 Use of serelaxin to reduce gdf-15

Publications (3)

Publication Number Publication Date
JP2017519008A JP2017519008A (ja) 2017-07-13
JP2017519008A5 true JP2017519008A5 (enExample) 2018-07-19
JP6820748B2 JP6820748B2 (ja) 2021-01-27

Family

ID=53476944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016572697A Expired - Fee Related JP6820748B2 (ja) 2014-06-13 2015-06-10 Gdf−15を減少させるためのセレラキシンの使用

Country Status (11)

Country Link
US (2) US20170100460A1 (enExample)
EP (1) EP3154559B1 (enExample)
JP (1) JP6820748B2 (enExample)
KR (1) KR20170018829A (enExample)
CN (1) CN106413740A (enExample)
AU (2) AU2015273097A1 (enExample)
BR (1) BR112016028833A2 (enExample)
CA (1) CA2952061A1 (enExample)
MX (1) MX2016016414A (enExample)
RU (1) RU2016147122A (enExample)
WO (1) WO2015189790A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
EP4005585B1 (en) 2013-11-21 2024-03-27 The Brigham & Women's Hospital, Inc. Compositions and methods for treating right ventricular hypertrophy
CA2956256A1 (en) 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
CN116327952A (zh) 2015-08-04 2023-06-27 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
DK3628049T3 (da) 2017-05-04 2023-08-14 Acceleron Pharma Inc Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf
CN114025675A (zh) * 2019-06-20 2022-02-08 索尼集团公司 信息处理装置、信息处理方法和程序

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660691C (en) * 2006-08-04 2020-01-14 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on gdf-15
ES2379104T3 (es) * 2007-05-24 2012-04-20 F. Hoffmann-La Roche Ag Métodos para evaluar el fallo cardíaco en pacientes con fibrilación auricular utilizando péptidos GDF-15
CA2724540C (en) * 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
MX2014000031A (es) * 2011-07-01 2014-07-09 Bayer Ip Gmbh Polipeptidos de fusion de relaxina y usos de los mismos.

Similar Documents

Publication Publication Date Title
JP2017519008A5 (enExample)
Myles et al. Importance of intraoperative oliguria during major abdominal surgery: findings of the restrictive versus liberal fluid therapy in major abdominal surgery trial
Ter Maaten et al. Diuretic response in acute heart failure—an analysis from ASCEND-HF
Yanishi et al. Factors associated with the development of sarcopenia in kidney transplant recipients
Peck-Radosavljevic et al. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II)
Behr The diagnosis and treatment of idiopathic pulmonary fibrosis
Amin et al. Effects of triiodothyronine replacement therapy in patients with chronic stable heart failure and low‐triiodothyronine syndrome: a randomized, double‐blind, placebo‐controlled study
JP2015501297A5 (ja) 医薬組成物、方法、診断キット
RU2016147122A (ru) Применение серелаксина для снижения gdf-15
Rodríguez et al. Recommendations of the Infectious Diseases Work Group (GTEI) of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) and the Infections in Critically Ill Patients Study Group (GEIPC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) for the diagnosis and treatment of influenza A/H1N1 in seriously ill adults admitted to the Intensive Care Unit
Karavanaki et al. Plasma high sensitivity C-reactive protein and its relationship with cytokine levels in children with newly diagnosed type 1 diabetes and ketoacidosis
JP2016520573A5 (enExample)
Zhang et al. The alleviative effects of metformin for lipopolysaccharide-induced acute lung injury rat model and its underlying mechanism
Lin et al. Preliminary prospective study to assess the effect of early blood urea nitrogen/creatinine ratio-based hydration therapy on poststroke infection rate and length of stay in acute ischemic stroke
Sarma et al. Safety, complications and outcome of large volume paracentesis with or without albumin therapy in children with severe ascites due to liver disease
Lazzeri et al. Mechanical ventilation in the early phase of ST elevation myocardial infarction treated with mechanical revascularization
Nazim et al. Metabolic control and its variability are major risk factors for microalbuminuria in children with type 1 diabetes
Faro et al. Left ventricular hypertrophy in children, adolescents and young adults with sickle cell anemia
Zhang et al. Value of three-dimensional speckle tracking echocardiography to assess left ventricular function in hyperuricemia patients
Gores et al. Plasma angiopoietin 2 concentrations are related to impaired lung function and organ failure in a clinical cohort receiving high-dose interleukin 2 therapy
Sharma et al. Alveolar macrophage activation in obese patients with obstructive sleep apnea
Dohi et al. CSF hypocretin-1/orexin-A concentrations in patients with subarachnoid hemorrhage (SAH)
Roberts et al. A novel way to investigate the effects of plasma exchange on antibiotic levels: Use of microdialysis
Csobay-Novák et al. Decreased plasma nociceptin/orphanin FQ levels after acute coronary syndromes
Rouini et al. Oral substitution of melatonin in critical care: a pharmacokinetic study in patients with intracranial hemorrhage